× Industry Reports Services Press Release Contact us About us

Asia Pacific In Vitro Diagnostics (IVD) Market Forecast 2027 By Test Type (Clinical Chemistry, Immunoassay/Immunochemistry, Molecular Diagnostics, Hematology, Urinalysis), By Product (Reagents & Kits, Instruments), By Application (Oncology, Infectious Diseases, Diabetes, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing/Pharmacogenomics), By End-Use (Hospitals, Diagnostic Laboratories, Academic & Research Institutes), Research Report, Country Outlook (China, Japan, India, South Korea, Australia, Indonesia, Singapore, Malaysia, Taiwan, Thailand, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: January 2022 | Publisher: Graphical Research Report ID: GR1012 | Delivery : PDF  Request Free Sample

Asia Pacific In Vitro Diagnostics (IVD) Market size surpassed USD 14 billion in 2020 and is set to observe around 5.4% growth rate between 2021 and 2027.

Increasing R&D activities in Asia Pacific region will boost the market growth. As there is rising prevalence of infectious diseases such as COVID-19, the demand for accurate in vitro diagnostics product is high. Such scenario forces market players to rise their R&D activities. Furthermore, government undertaken various initiative to boost the in vitro diagnostics market in Asia Pacific. For instance, in June 2021, the Indian government launched Production Linked Incentive Scheme (PLI 2.0) aims to improve India's manufacturing capabilities by increasing investment and production in the IVD sector.

Asia Pacific Market, By Product Type

The instrument segment exceeded USD 4.4 billion revenue in 2020, attributed to rising focus of towards development of advanced in vitro diagnostics instrument and increasing popularity of these instrument in diagnostics centres and hospitals.

Furthermore, new product launches will accelerate overall market demand. For instance, in March 2021, OpGen received regulatory approval from the Chinese National Medical Products Administration for its advanced in vitro diagnostics instrument system. Moreover, outsourcing in instrumentation is increasing gradually instead of in-house instrumentation, owing to low operating costs and increased efficiency and speed.

Asia Pacific Market, By Test Type

The molecular diagnostics segment in the Asia Pacific IVD market will witness 6% CAGR during the forecast timeline. Molecular diagnostic tests are used to detect certain sequences in RNA or DNA that may or may not relate to any disease. Molecular diagnostics are mostly employed to diagnose infectious diseases, and the segment is expected to grow significantly due to the increased burden and spread of the COVID-19 pandemic. Additionally, to reduce the burden of COVID-19 pandemic major companies in this region focusing on introduction of advance diagnostics product. For instance, in August 2021, Seimens Healthineers, a German technology company announced that it will manufacture molecular testing kits in India. The company will begin producing molecular testing kits, including COVID-19 testing -IMDX SARS-CoV2 Multiplex RTPCR - and other molecular testing kits.

Asia Pacific In Vitro Diagnostics Market, By Application

The drug testing/pharmacogenomics segment accounted more than USD 1 billion revenue in 2020. This is due to increasing cases of drug abuse in the region. There is a growing need for comprehensive drug testing legislation in order to limit cases and provide proper treatment. Indians are heavily reliant on alcohol, opioids, cannabis, and drug abuse is more prevalent the country.

Moreover, Because of the COVID-19 pandemic, fingerprint-based drug testing, a relatively new concept, has gained more popularity in recent years. Due to the possibility of infection transmission, the COVID-19 pandemic has made drug testing in labs, hospitals, and other facilities difficult. Fingerprint-based drug testing can help to reduce the spread of COVID-19 because it is non-invasive, less time-consuming, hygienic, allows for social distancing.

Asia Pacific Market, By End-Use

The hospitals segment held over 40% Asia Pacific in vitro diagnostics market share in 2020, owing to increasing number of hospitals and independent testing laboratories in Asia Pacific.

Moreover, high demand of diagnostics amid COVID-19 pandemic coupled with increasing investment in healthcare industry will boost the industry growth. In addition, rising number of hospital admission due to increasing prevalence of chronic illness is a positive impact rendering factor.

Asia Pacific Market, By Country

The Japan IVD market revenue was around USD 2.7 billion in 2020and is poised to record a CAGR of 5.4% till 2027. Market growth is supported by presence of independent diagnostic centres, hospitals, and academic institutes.

Several countries including India, Japan, and China are witnessing increasing demand for in vitro diagnostic tests due to surging geriatric population and escalating prevalence rates of infectious and chronic diseases. Furthermore, government funding on healthcare infrastructure and launch of new diagnostic kits in the country will fuel the market expansion.

Competitive Industry Landscape

Some of the key industry leaders operating in the Asia Pacific in vitro diagnostics (IVD) market include F. Hoffmann-La Roche AG, Abbott, Danaher, Siemens Healthineers, BioMerieux, DiaSorin, Bio-Rad Laboratories, Sysmex Corporation, Thermo Fisher Scientific, Qiagen, Ortho Clinical Diagnostics Becton, Dickinson and Company.

Frequently Asked Question(FAQ) :

The market size for in vitro diagnostics (IVD) in Asia Pacific had exceeded USD 14 billion in 2020 and will exhibit a CAGR of around 5.4% through 2027 with the increasing R&D activities in the region.
Instrument segment had recorded valuation of over USD 4.4 billion in 2020 with the increasing focus on technological advancements and rising popularity of these instruments in the regional diagnostics centers and hospitals.
Molecular diagnostics segment will witness a CAGR of over 6% through 2027 with the increasing need to detect certain sequences in RNA or DNA that may relate to any disease.
The market for IVD in Japan will record a CAGR of 5.4% through 2027 on account of the strong presence of various independent diagnostic centers, hospitals, and academic institutes.
The major companies operating in the market include F. Hoffmann-La Roche AG, Abbott, Danaher, Siemens Healthineers, BioMerieux, DiaSorin, Bio-Rad Laboratories, Sysmex Corporation, Thermo Fisher Scientific, Qiagen, Ortho Clinical Diagnostics Becton, Dickinson and Company.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]